49. 全身性エリテマトーデス Systemic lupus erythematosus Clinical trials / Disease details


臨床試験数 : 946 薬物数 : 722 - (DrugBank : 186) / 標的遺伝子数 : 117 - 標的パスウェイ数 : 199

  
6 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2005-001391-12-GB
(EUCTR)
12/10/200515/06/2005A multi-national, multi-centre, randomized, double-blind, placebo-controlled, multiple-dose, parallel-group study to assess the efficacy, tolerability and safety of three doses of edratide (TV-4710) for injection administered subcutaneously to systemic lupus erythematosus (SLE) patients - PRELUDEA multi-national, multi-centre, randomized, double-blind, placebo-controlled, multiple-dose, parallel-group study to assess the efficacy, tolerability and safety of three doses of edratide (TV-4710) for injection administered subcutaneously to systemic lupus erythematosus (SLE) patients - PRELUDE Systemic lupus erythematosus (SLE)
MedDRA version: 7.1;Level: PT;Classification code 10042945
Product Name: edratide
Product Code: TV-4710
INN or Proposed INN: edratide
TEVA Pharmaceutical Industries, Ltd.NULLNot Recruiting Female: yes
Male: yes
260 Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): noHungary;Spain;Germany;Italy;United Kingdom
2EUCTR2005-001391-12-DE
(EUCTR)
23/09/200515/07/2005A multi-national, multi-centre, randomized, double-blind, placebo-controlled, multiple-dose, parallel-group study to assess the efficacy, tolerability and safety of three doses of edratide (TV-4710) for injection administered subcutaneously to systemic lupus erythematosus (SLE) patients - PRELUDEA multi-national, multi-centre, randomized, double-blind, placebo-controlled, multiple-dose, parallel-group study to assess the efficacy, tolerability and safety of three doses of edratide (TV-4710) for injection administered subcutaneously to systemic lupus erythematosus (SLE) patients - PRELUDE Systemic lupus erythematosus (SLE)
MedDRA version: 7.1;Level: PT;Classification code 10042945
Product Name: edratide
Product Code: TV-4710
INN or Proposed INN: edratide
TEVA Pharmaceutical Industries, Ltd.NULLNot RecruitingFemale: yes
Male: yes
260Hungary;United Kingdom;Germany;Spain;Italy
3EUCTR2005-001391-12-ES
(EUCTR)
01/09/200507/07/2005A multi-national, multi-centre, randomized, double-blind, placebo-controlled, multiple-dose, parallel-group study to assess the efficacy, tolerability and safety of three doses of edratide (TV-4710) for injection administered subcutaneously to systemic lupus erythematosus (SLE) patients - PRELUDEA multi-national, multi-centre, randomized, double-blind, placebo-controlled, multiple-dose, parallel-group study to assess the efficacy, tolerability and safety of three doses of edratide (TV-4710) for injection administered subcutaneously to systemic lupus erythematosus (SLE) patients - PRELUDE Systemic lupus erythematosus (SLE)
MedDRA version: 7.1;Level: PT;Classification code 10042945
Product Name: edratide
Product Code: TV-4710
INN or Proposed INN: edratide
Product Name: edratide
Product Code: TV-4710
INN or Proposed INN: edratide
Product Name: edratide
Product Code: TV-4710
INN or Proposed INN: edratide
TEVA Pharmaceutical Industries, Ltd.NULLNot RecruitingFemale: yes
Male: yes
260Phase 2Hungary;Spain;Germany;Italy;United Kingdom
4EUCTR2005-001391-12-IT
(EUCTR)
28/07/200523/03/2006A Multi-National, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose, Parallel Group Study to Assess the Efficacy, Tolerability and Safety of Three Doses of Edratide TV-4710 for Injection Administered Subcutaneously to Systemic Lupus Erythematosus SLE patientsA Multi-National, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose, Parallel Group Study to Assess the Efficacy, Tolerability and Safety of Three Doses of Edratide TV-4710 for Injection Administered Subcutaneously to Systemic Lupus Erythematosus SLE patients Treatment of active SLE patients who are concurrently undergoing a regimented program of decreased steroid use.
MedDRA version: 6.1;Level: PT;Classification code 10042945
Product Name: Edratide Acetate
Product Code: TV-4710
Product Name: Edratide Acetate
Product Code: TV-4710
Product Name: Edratide Acetate
Product Code: TV-4710
TEVANULLNot RecruitingFemale: yes
Male: yes
260Hungary;Germany;United Kingdom;Spain;Italy
5EUCTR2005-001391-12-HU
(EUCTR)
27/07/200515/06/2005A multi-national, multi-centre, randomized, double-blind, placebo-controlled, multiple-dose, parallel-group study to assess the efficacy, tolerability and safety of three doses of edratide (TV-4710) for injection administered subcutaneously to systemic lupus erythematosus (SLE) patients - PRELUDEA multi-national, multi-centre, randomized, double-blind, placebo-controlled, multiple-dose, parallel-group study to assess the efficacy, tolerability and safety of three doses of edratide (TV-4710) for injection administered subcutaneously to systemic lupus erythematosus (SLE) patients - PRELUDE Systemic lupus erythematosus (SLE)
MedDRA version: 7.1;Level: PT;Classification code 10042945
Product Name: edratide
Product Code: TV-4710
INN or Proposed INN: edratide
TEVA Pharmaceutical Industries, Ltd.NULLNot RecruitingFemale: yes
Male: yes
260Hungary;Germany;United Kingdom;Spain;Italy
6NCT00203151
(ClinicalTrials.gov)
July 200513/9/2005A Study to Evaluate the Tolerability, Safety and Effectiveness of Edratide in the Treatment of LupusA Multi-National, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose, Parallel Group Study to Assess the Efficacy, Tolerability and Safety of Edratide for Subcutaneous Injection in Systemic Lupus Erythematosus (SLE)Systemic Lupus ErythematosusDrug: edratideTeva Pharmaceutical IndustriesNULLTerminated18 Years65 YearsBoth340Phase 2United States